Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1264 | Obesity | ICEECE2012

Bariatric surgery in men: effects on gonadal hormones, body composition, glucose, lipid and bone metabolism

Aarts E. , van Wageningen B. , Loves S. , Janssen I. , Berends F. , Sweep F. , de Boer H.

Background: Obesity-related, isolated hypogonadotropic hypogonadism (IHH) occurs in more then 40% of morbidly obese men.Hypothesis: IHH and prolonged persistence of low testosterone levels after bariatric procedures may reduce the beneficial effects of surgery.Objective: To evaluate the impact of IHH on the results of bariatric surgery.Patients and methods: observational study with measurement of gonadal horm...

ea0026p328 | Obesity | ECE2011

Letrozole normalizes serum testosterone but has no clinical effects in men with obesity-related hypogonadotropic hypogonadism

Loves S , de Jong J , van Sorge A , Telting D , Hermus A , de Boer H

Introduction: Hypogonadotropic hypogonadism is frequently observed in morbidly obese men, due to aromatase-dependent conversion of androgens to estrogens. The clinical impact of this sex hormone imbalance is unknown.Aim: Evaluate the clinical effects of aromatase inhibition in obesity-related hypogonadism.Methods: Double-blind, placebo-controlled, 6-month trial in severely obese men (BMI>35 kg/m2) with obesity-relate...

ea0026p205 | Pituitary | ECE2011

LHRH-antagonist cetrorelix may reduce postmenopausal flushing

van Gastel P M , van der Zanden M , Telting D , Filius M , Bansci L , de Boer H

Background: Estrogen replacement therapy is the most effective treatment for postmenopausal (PMP) flushing, but its use is often contraindicated. An effective and safe alternative is urgently needed.Aim: To explore the effects of the LHRH receptor antagonist cetrorelix in women with severe PMP flushing who have a mean daily flush score >15.Methods: Open-label treatment with cetrorelix 250 μg twice a day in nine women with ...